Analyst Rating Update on Synthetic Biologics Inc (SYN)

Synthetic Biologics Inc (NYSEMKT:SYN) : 4 brokerage houses believe that Synthetic Biologics Inc (NYSEMKT:SYN) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 5 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.2.

Synthetic Biologics Inc (NYSEMKT:SYN) : 4 investment research analysts covering Synthetic Biologics Inc (NYSEMKT:SYN) have an average price target of $9 for the near short term. The highest target price given by the Brokerage Firm to the stock is $10 and the lowest target is $8 for the short term. Analysts expect the variance to be within $0.82 of the average price.

For this week, the average consensus of the company shares are rated as a Strong Buy.

Synthetic Biologics Inc (NYSEMKT:SYN): stock turned positive on Tuesday. Though the stock opened at $1.71, the bulls momentum made the stock top out at $1.81 level for the day. The stock recorded a low of $1.68 and closed the trading day at $1.76, in the green by 7.32%. The total traded volume for the day was 738,543. The stock had closed at $1.64 in the previous days trading.

Synthetic Biologics, Inc. is a clinical-stage biotechnology company. The Company is developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C) and a monoclonal antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase II oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.